This novel treatment strategy might give rise to possible adjuvant therapies for the current PD-1/PD-L1 blockade Abs, offering significant therapeutic benefits to CRC patients with intrinsic unresponsiveness and/or acquired resistance to the immune checkpoint therapies at present. The gene discussed is CD274; the disease is colorectal carcinoma.